Liver Transplant clinical trials at UCSD
6 in progress, 2 open to eligible people
HOPE in Action Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients
open to eligible people ages 18 years and up
The primary objective of this study is to determine if an HIV-infected donor liver (HIVD+) transplant is safe with regards to major transplant-related and HIV-related complications
San Diego, California and other locations
Sponsor-Initiated OCS Liver Perfusion (OLP-II) Registry
open to all eligible people
OLP-II Registry is a sponsor-initiated, multi-center, observational, post-approval registry.
La Jolla, California and other locations
COVID Protection After Transplant-Immunosuppression Reduction
Sorry, in progress, not accepting new patients
This study will enroll individuals who have: - Completed primary series of mRNA COVID-19 vaccine, and - An antibody response ≤ 2500 U/mL measured at least 30 days after the last dose of vaccine. This group of patients is at high risk for severe COVID-19 disease due to pharmacologic immunosuppression and a high prevalence of non-transplant risk factors such as obesity and diabetes.
San Diego, California and other locations
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
Sorry, not currently recruiting here
This is a multi-center clinical trial in Cytomegalovirus (CMV) seronegative prospective liver transplant recipients to determine the efficacy of two doses of Cytomegalovirus-Modified Vaccinia Ankara (CMV-MVA) Triplex CMV vaccine pre-transplant. The primary objective is to assess the effect of pre-transplant (Tx) Triplex vaccination on duration of CMV antiviral therapy (AVT) within the first 100 days post-Tx in CMV seropositive donor (D+) and seronegative (R-) (D+R-) liver transplant recipients (LTxRs). A protocol-mandated preemptive therapy (PET) will be used for CMV disease prevention in D+R- LTxRs.
La Jolla, California and other locations
Molecular Assessment and Profiling of Liver Transplant Recipients
Sorry, not currently recruiting here
The objective of this protocol is to conduct longitudinal and prospective studies of liver transplant recipients, using a multimodality approach, akin to that used in kidney transplantation. The primary aim will compare the clinical outcomes of LiverCare post-transplant surveillance in liver transplant with standard of care consisting of liver function tests, DSA measurements, drug level monitoring, and 'for cause' biopsy. The protocol will assess the correlation between clinical events (e.g. rejection, recurrent disease, biliary obstruction), dd-cfDNA levels, gene expression profiling, ability to assess microchimerism, develop predictive analytics, infectious disease diagnoses and finally examine graft histology.
San Diego, California and other locations
OCS Liver Perfusion (OLP) Post-Approval Registry
Sorry, in progress, not accepting new patients
The objective of the OLP Registry is to collect more data on the post-transplant clinical outcomes of DBD and DCD donor livers preserved and assessed on OCS Liver System according to the approved indication and the OCS device performance in the real-world setting.
La Jolla, California and other locations
Our lead scientists for Liver Transplant research studies include Gabriel Schnickel, MD, MPH Saima Aslam, MD.
Last updated: